Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision medicine treatment modality, today announced its launch backed by $20 million financing led by Khosla Ventures. Other investors in the syndicate included Upfront Ventures, Revolution, BOLD Capital, and Compound. Proceeds from the financing support the advancement of the Company's lead therapeutic program in glioma through preclinical development, as well as help advance its program in Huntington's disease.

Bionaut Labs is focused on revolutionizing the treatment of central nervous system disorders with its Bionaut™ precision medicine treatment modality that uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted disease areas. With the Bionaut™ medical modality, Bionaut Labs can transform the way the biopharmaceutical industry develops treatments, allowing the Company to engineer the therapeutic index for better efficacy and safety. Led by a world-class team of medical, engineering, and drug development experts, Bionaut Labs' headquarters is in Los Angeles, California, with additional R&D sites in Israel and at the Max Planck Institute in Germany. For more information, please visit www.bionautlabs.com.